1. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer

   • Ronald M. Bukowski

   Clinical Trials Report 10 February 2009 Pages: 81 - 83

2. Myeloid-derived suppressor cells: A novel therapeutic target

   • Jennifer S. Ko
   • Ronald M. Bukowski
   • James H. Fincke

   OriginalPaper 10 February 2009 Pages: 87 - 93

3. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

   • C. Lance Cowey
   • W. Kimryn Rathmell

   OriginalPaper 10 February 2009 Pages: 94 - 101

4. Perifosine: Update on a novel Akt inhibitor

   • Joell J. Gills
   • Phillip A. Dennis

   OriginalPaper 10 February 2009 Pages: 102 - 110

5. Angiopoietin-2: Development of inhibitors for cancer therapy

   • Bo Hu
   • Shi-Yuan Cheng

   OriginalPaper 10 February 2009 Pages: 111 - 116

6. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

   • Jacqueline Sayyah
   • Peter P. Sayeski

   OriginalPaper 10 February 2009 Pages: 117 - 124

7. The chemokine receptors CXCR4 and CXCR3 in cancer

   • Amy M. Fulton

   OriginalPaper 10 February 2009 Pages: 125 - 131

8. Sarcomas of the head and neck region

   • Thomas D. Shellenberger
   • Erich M. Sturgis

   OriginalPaper 10 February 2009 Pages: 135 - 142

9. Quality of life of oropharyngeal cancer patients treated with brachytherapy

   • David N. Teguh
   • Peter C. Levendag
   • Paul I. M. Schmitz

   OriginalPaper 10 February 2009 Pages: 143 - 150

10. Surgical salvage of cancer of the oropharynx after chemoradiation

    • Jeffrey M. Bumpous

    OriginalPaper 10 February 2009 Pages: 151 - 155

11. Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies

    • Steve C. Lee
    • Andrés López-Albaitero
    • Robert L. Ferris

    OriginalPaper 10 February 2009 Pages: 156 - 162